ArticleBMC cardiovascular disorders2026
Economic and clinical impact of diagnostic sensitivity for the use of insertable cardiac monitors to detect atrial fibrillation in cryptogenic stroke patients in the United Kingdom.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsertable cardiac monitors (ICMs) are recommended by international clinical guidelines for prolonged cardiac monitoring in patients with cryptogenic stroke (CS). However, only LINQ ICM has been recognised as cost-effective by the National Institute for Health and Care Excellence (NICE) for this indication, as other ICMs may vary in diagnostic yield. It is unclear how this might impact patient outcomes and cost-effectiveness. This study aims to evaluate the clinical and economic impacts of different diagnostic sensitivity levels of ICMs for detecting atrial fibrillation (AF) in CS patients from the perspective of the UK National Health Service (NHS).
methodsWe built a Markov model with a three-month cycle and a lifetime horizon to assess the cost-effectiveness of ICMs. Patient characteristics and detection probabilities were taken from the CRYSTAL-AF trial, which compared ICM use with the standard of care (SoC), with costs sourced from NHS. Upon detection of AF, patients transition to direct oral anticoagulants to prevent secondary ischaemic stroke (IS). Outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). Scenario analyses were performed to examine various levels of AF detection sensitivity levels.
resultsLINQ ICM versus SoC resulted in an ICER of £8,670 per QALY, below the NICE willingness-to-pay threshold. Compared with a hypothetical ICM with 30% points lower sensitivity, AF was 37.5% more likely to be detected during long-term follow-up, leading to a 9.5% reduction in the odds of recurrent IS. The lower sensitivity ICM is less cost-effective as a result, with an ICER of £13,479 per QALY versus SoC. These results remain robust under sensitivity analyses.
conclusionDiagnostic sensitivity substantially impacts the clinical outcomes of ICMs for prolonged cardiac monitoring as well as the cost-effectiveness. ICMs with modestly lower sensitivity than LINQ are likely to be less effective at detecting AF, leading to increased stroke risks and costs, and thereby be less cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.